){kind=logo}
Modulant Biosciences
)
Modulant Biosciences is a biotechnology company developing antivirals that work via a completely novel mechanism: targeting host proteins and halting viral capsid assembly, the final step in viral replication. The compounds target abnormal host proteins, minimizing side effects and preventing virus resistance. Our first product is intended for PRRSv outbreaks in pigs.
Modulant’s host-targeted small molecules return abnormal proteins back to their normal state and restore homeostasis. This works for plants and animals affected by viral or other infectious diseases and can treat chronic progressive diseases such as cancer and kidney disease.
- About their product/solution: Small molecule, host-directed antivirals for PRRSv, PEDV and SIV.
- No. of employees: 2
- Founded in: 2023
- Raised so far: $750,000 + research partnership
- Backed by: Angel Investor
- Looking to engage with: Investors, producers, animal health pharma, potential research partners
)
){kind=logo}
)
)
)
)
)
)
)
)
)
)